ORBIMED ADVISORS LLC

Q2 2025 13F-HR Holdings

Location
New York, NY
Holdings as of
6/30/2025
Date filed
8/14/2025
Form type
13F-HR
Num holdings
102
Total value ($000)
$4,004,111
Net value change ($000)
-190,535 (-4.5%)
New positions
14
Sold out positions
23
Turnover %
14.5%
Sector allocation + QoQ delta (equities-only)

Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown

Prev filing: 5/15/2025 Next filing: 11/14/2025 SEC filing

Snapshot: Change Analysis

Compared to Q1 2025
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
CAI 81,091 NEW
SPRY 40,366 38.7%
ROIV 31,324 NEW
UPB 27,671 79.4%
SION 25,527 65.9%
NTRA 22,904 29.6%
EW 22,544 20.3%
THC 19,297 30.9%
CTMX 19,208 NEW
BSX 18,370 6.5%
Top Reduces (Value $000, Stocks/ETFs)
EWTX -127,031 -38.4%
PFE -97,564 -100.0%
IONS -76,636 -100.0%
NBIX -48,251 -46.7%
TMO -45,336 -70.6%
SpringWorks Therapeutics, Inc. -41,932 -100.0%
XTNT -34,364 -100.0%
TARS -25,566 -76.1%
CYTK -25,071 -41.3%
ITGR -24,887 -31.8%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 27,469 (0.7% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type